key: cord-1000117-wh659mlg
authors: Langford, Bradley J.; So, Miranda; Leung, Valerie; Raybardhan, Sumit; Lo, Jennifer; Kan, Tiffany; Leung, Felicia; Westwood, Duncan; Daneman, Nick; MacFadden, Derek R.; Soucy, Jean-Paul R.
title: Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression
date: 2021-11-26
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.11.008
sha: e17be6662771f0a73c4c60dd5d3da38862288704
doc_id: 1000117
cord_uid: wh659mlg

OBJECTIVE: To identify risk factors and microbiology associated with respiratory and bloodstream bacterial infection in patients with COVID-19. METHODS: Data Sources: We searched MEDLINE, OVID Epub and EMBASE for published literature up to February 5, 2021. Study eligibility criteria: Studies including at least 50 patients with COVID-19 in any healthcare setting. Assessment of risk of Bias: We used a validated 10-item risk of bias tool for disease prevalence Methods of data synthesis: The main outcome of interest was the proportion of COVID-19 patients with bloodstream and/or respiratory bacterial co-infection and secondary infection. We performed meta-regression to identify study population factors associated with bacterial infection including healthcare setting, age, comorbidities and COVID-19 medication. RESULTS: Out of 33,345 studies screened, 171 were included in the final analysis. Bacterial infection data were available from 171,262 patients. The prevalence of co-infection was 5.1% (95% CI: 3.6% to 7.1%) and secondary infection was 13.1% (95% CI: 9.8% to 17.2%). There was a higher odds of bacterial infection in studies with a higher proportion of patients in the intensive care unit (ICU) (adjusted OR 18.8, 95% CI: 6.5 to 54.8). Female sex was associated with a lower odds of secondary infection (adjusted OR 0.73, 95% CI: 0.55 to 0.97) but not co-infection (adjusted OR 1.05, 95% CI: 0.80 to 1.37). The most common organisms isolated included Staphylococcus aureus, coagulase-negative Staphylococci, and Klebsiella species. CONCLUSIONS: While the odds of respiratory and bloodstream bacterial infection are low in patients with COVID-19, meta-regression revealed potential risk factors for infection, including ICU setting and mechanical ventilation. The risk for secondary infection is substantially greater than the risk for co-infection in patients with COVID-19. Understanding predictors of co-infection and secondary infection may help to support improved antibiotic stewardship in patients with COVID-19. REGISTRATION: PROSPERO (ID CRD42021241098).

There is rising concern about the long-term impact of COVID-19 on antimicrobial resistance.

While bacterial co-infection rates in patients presenting with COVID-19 have been found to be low (<5%) (1, 2) , the majority (50 -75%) of hospitalized patients with COVID-19 receive antibiotics (3, 4) . The rates of secondary bacterial infection, those that occur later on in illness, tend to be higher (10-20%), but are typically related to healthcare-associated infections involving invasive devices, such as ventilators and central venous access (1, 5, 6) . There are limited data describing the causative pathogens and their susceptibility patterns among COVID-19 patients with bacterial co-infections.

Despite the low rate of infection early in illness, a large observational study found that 57% of patients with COVID-19 received early empiric antibiotics and 46% of these patients had their antibiotics continued after a positive COVID-19 PCR test. Of those who had antibiotics continued despite no confirmed bacterial infection, 64% had antibiotics continued for five or more days (3) . 

We conducted a rapid systematic review guided by the Cochrane Rapid Reviews Methods Group (7) to evaluate concomitant bacterial infection in patients with COVID-19. We included studies of humans with COVID-19, across all healthcare settings (i.e., hospital, community, longterm care), and age groups (pediatric and adult patients).

We included cohort studies, case series with 50 or more patients and randomized controlled trials that did not evaluate antibiotic use as an intervention, but excluded reviews, editorials, letters, and case studies. We excluded studies that 1) included patients with non-laboratoryproven COVID-19, 2) tested for co-infection using only nasopharyngeal swabs, 3) did not differentiate between bacterial infection and other co-infections or secondary infections (e.g., fungal), 4) indicated bacterial infection was presumed or suspected (e.g., use of white blood cell count, biomarkers), and 5) used serology as a bacterial infection diagnostic approach. This protocol was registered under PROSPERO, the international registry of systematic reviews (ID CRD42021241098).

We performed systematic searches of MEDLINE, OVID Epub, and EMBASE databases for published literature in any language from January 1, 2019 to February 5, 2021 with assistance from a medical library information specialist. The expanded timeline aimed to capture new publication since the systematic search we performed for our earlier review (January 1, 2019 to April 16, 2020) (8) . The current search was structured to include COVID-19 terms co-infection, bacterial infection, respiratory infection, epidemiology, or descriptive cohort study terms. The complete search strategy is described in the Online Supplement. The results of the search were J o u r n a l P r e -p r o o f imported into Covidence (Covidence, Melbourne, Australia), an online software tool for systematic reviews. Duplicate records were removed using Covidence.

Initial screening of titles and abstracts from the search were shared by two authors (BL or VL), who independently identified studies that met all inclusion criteria and none of the exclusion criteria. All full text studies meeting initial criteria were then reviewed by one of the authors (BL, MS, VL, SR, TK, JL, or DM) for final inclusion in the rapid review. Single screening was utilized given the high volume of citations and the substantial kappa agreement (0.62 to 0.68) from our team for previous rapid reviews in which duplicate screening was performed (9) .

One of seven authors (BL, MS, VL, SR, TK, JL, or DM) independently extracted data from included studies using a standardized data collection form. For quality assurance, one of three authors (FL, VL or BL) then verified all extracted data to confirm accuracy and completeness.

We collected data on the following variables for demographics and setting: author; country of study; start and end dates; study design; healthcare setting (inpatient ICU vs. non ICU, outpatient); sample size; age group; patient population; mean or median age; and number of female patients. Regarding clinical characteristics, we collected information on COVID-19 severity; number of patients requiring mechanical ventilation; number of patients that were smokers; number of patients with comorbidities (chronic obstructive pulmonary disease, cardiovascular disease, or diabetes); and number of patients who were prescribed corticosteroids, interleukin-6 (IL-6) inhibitors (i.e., tocilizumab or sarilumab), and antibacterial agents. We extracted respiratory and bloodstream microbiology data, including specimen source and identification, if the information was available.

We used a validated 10-item risk of bias tool for disease prevalence (10) . Risk of bias was categorized as low (score ≥ 8), moderate (score 5-7), or high (score 0-4). A sensitivity analysis J o u r n a l P r e -p r o o f 6 was performed stratifying proportion of bacterial infection by study risk of bias. Additional sensitivity analyses were performed to 1) remove studies where bacteriological testing method and bacterial infection source were not specified and 2) to stratify studies based on whether they used a clinical definition for bacterial infection (e.g., differentiated infection from colonization or contamination using clinical criteria).

The main outcome of interest was the overall prevalence of respiratory and bloodstream First, studies were categorized based on whether they evaluated co-infection (authors used the term co-infection and/or specified that infection was assessed on admission or at the time of health care visit), secondary infection (authors used the term secondary infection, superinfection, healthcare-associated infection, and/or indicated that infection was identified >48 hours after initial assessment). Studies that did not specify co-infection or secondary infection were grouped with co-infection. To estimate overall bacterial infection, for studies reporting both co-infection and secondary infection, we selected the higher proportion of the two.

Second, the source of infection was categorized as respiratory, bloodstream, both respiratory and bloodstream, or not specified. Infections specified from other sources (e.g., urine, skin)

were not included. For the purposes of this study, both co-infection and secondary infection were limited to respiratory and/or bloodstream specimens to estimate the prevalence of infections closely linked to COVID-19 while limiting bias due to variability in diagnosis of other less relevant conditions (e.g., skin and soft tissue infections and urinary tract infections).Third, studies were categorized based on the bacteriological testing method (culture, nucleic acid amplification, a combination of approaches, or not specified).

We pooled proportion data across studies via a random-effects meta-analysis using a generalized linear mixed model (GLMM) with logit link approach (11, 12) . Results were illustrated using forest plots stratified by healthcare setting and infection type. Heterogeneity was assessed by I 2 statistic (13) . All analyses were carried out using R version 4.1.1 with the packages metafor and meta. The statistical code for this analysis is made available online (14) .

To predict the effect of specific population-level variables on bacterial infection, we performed univariable meta-regression evaluating patient characteristics (age, sex, comorbidities, use of medication for treatment of COVID-19 ), markers of severity (e.g., mechanical ventilation), healthcare setting, geographic region (Asia, Middle East, Europe, North America, South America), and end-month of study. Differences in prevalence of antibiotic prescribing for each variable were described in terms of the prevalence odds ratio (OR) compared to reference, per 10% increase for continuous variables and per 10 year increase for age. Multi-variable metaregression was then performed to account for key factors mediating the risk of infection including mean/median patient age (15) and severity of COVID-19 (an index including the highest value of: % of patients with ARDS; % of ICU patients; % of mechanical ventilation patients) (16) . One model per variable was constructed, and only studies where both the variable of interest and the adjustment variables were reported were included. We used the same subset of studies with available data for both the unadjusted and adjusted analyses. Given studies that did not report whether they evaluated co-infection vs. secondary infection were grouped with co-infection, a sensitivity analysis was performed to remove these studies with unspecified outcome to determine the robustness of our findings.

Of 56,767 studies identified via searching, after duplicate removal, we reviewed a total of 33,345 studies via title and abstract screening, 1,798 of which were assessed via full-text screening. We included 171 studies in the final analysis (3, (Figure 1 ). Study design was primarily retrospective in nature (n=149), with fewer prospective cohorts (n=19), or randomized controlled trials (n=3). COVID-19 study data was collected from December 2019 to October 2020.

The majority of studies took place in Europe (67, 39%), followed by Asia (55, 32%), North America (34, 20%), Middle East (10, 6%), South and Central America (3, 2%), and multiple regions (2, 1%).

Most studies took place in a general hospital setting (129, 75%), followed by only intensive care unit (ICU) patients (33, 19%) , mixed hospitalized patients and outpatients (9, 5%), and a single study limited to outpatients (1, 1%).

A total of 171,262 patients were evaluated for bacterial infection across the 171 studies. A median 41% of participants were female (interquartile range (IQR) 33 to 48%). The median age was 61 years (IQR 53 to 64, range 5 to 85). Only four studies included a population with a median age less than 18 years. Studies included a median of 25% ICU patients (IQR 13 to 100%) and a median of 21% (IQR 10 to 52%) patients receiving mechanical ventilation. Smokers comprised a median of 9% (IQR 5 to 22%) of the study populations. Common comorbidities included chronic respiratory disease (median 6%, IQR 4 to 12%), cardiovascular disease (median 14%, IQR 6 to 20%), and diabetes (median 21%, IQR 12 to 32%).

J o u r n a l P r e -p r o o f Most studies did not specify how bacterial infection was detected (82, 48%), followed by studies using culture methods (72, 42%), combined approach using culture with nucleic acid amplification and/or urinary antigen testing (16, 9%), and nucleic acid amplification alone (1, 

A total of 76 studies specified organism identification for bacterial infections (co-infections n=1,319 and secondary infections n=2,016). For co-infections, the most common bacterial organisms identified included Staphylococcus aureus (S. aureus) (332, 25%), coagulase-negative Staphylococcus (CNST) (217, 16%), and Klebsiella species (113, 9%). For secondary infections, identified organisms were more diverse but the most common organisms were similar including S. aureus (315, 16%) and Klebsiella species (233, 11%). Figure 2 contains complete details for all organisms identified.

When pooling bacterial infection across all 171,262 patients with COVID-19, the prevalence of overall respiratory and/or bloodstream bacterial infection was 8.8% (95% CI: 6.9 to 11.1%).

Bacterial co-infection occurred in 5.1% (95% CI: 3.6 to 7.1%) of patients and increased with the level or intensity of care, from mixed hospital/outpatient populations (1.9%, 95% CI: 0.5 to 7.1%), to hospitalized patients (4.4%, 95% CI: 3.0 to 6.4%), to intensive care only (15.4%, 95% CI: 10.5 to 22.0%). Secondary bacterial infection was more common at 13.1% (95%CI: 9.8% to 17.2%). While mixed hospital/outpatient populations (11.1%, 95% CI: 1.4 to 52.3%) and respiratory and blood isolates (co-infection 6.2%, 95% CI: 3.6 to 10.5%; secondary infection: 16 .3%, 11.9 to 22.0%), blood alone (co-infection 6.0%, 95% CI 3.4 to 10.3%; secondary infection: 10 .7%, 95% CI 3.4 to 28.8%), and respiratory isolates alone (co-infection 2.9%, 95% CI 1.6 to 4.9%; secondary infection 12.2%, 95% CI: 4.9 to 27.1%). See Figure 3 .

COVID-19 co-infection rates were higher in studies with a higher proportion of ICU patients 

Although the overall estimate of bacterial infection was similar when stratified by study risk of bias, studies with a moderate risk of bias reported numerically higher rates of bacterial When removing studies that did not explicitly state whether they evaluated co-infection vs.

secondary infection, the findings were similar, with one key exception. ICU setting did not appear to be associated with co-infection risk after removing these studies (adjusted OR 3.61 95%CI 0.46 to 28.36); however, the association between ICU setting and secondary infection risk persisted, adjusted OR 32.10 (95%CI 2.66 to 387.30).

Out of 31,802 patients evaluated for antibiotic prescribing, the prevalence of antibiotic use in patients with COVID-19 was 76.2% (95%CI: 67.3 to 83.2%). There did not appear to be an appreciable change in prescribing over time during the period January to September 2020.

There was substantial heterogeneity between studies in the prevalence of antibiotic prescribing A series of pivotal studies established two classes of immunotherapy, systemic corticosteroids and IL-6 inhibitors, as standards of care for patients with moderate to severe acute respiratory distress syndrome requiring hospitalization requiring respiratory support (188) (189) (190) (191) . Given their immunomodulatory effects, concern has been raised regarding their role in secondary infections in COVID-19. Our analyses did not identify a significantly higher odds of secondary bacterial infections among patients exposed to corticosteroids or IL-6 inhibitors. These findings may reflect the fact that other drivers, such as the inflammatory response to SARS-CoV-2 and invasive devices, are more significant contributing factors of bacterial infections in patients with COVID-19 (192) and as such there may be limited benefit of empiric antibiotics in the absence of proven infection for patients receiving these agents. Alternatively, our study may not be adequately powered to detect the impact of these immunomodulatory agents on secondary infections, given the relatively low rate of bacterial infection events.

The most common organisms identified in patients with both co-infection and secondary infection are S. aureus, CNST, and Klebsiella species. These pathogens reflect those seen in hospital-acquired pneumonia and bloodstream infections also seen outside of the context of J o u r n a l P r e -p r o o f COVID-19 (193, 194) . However, given most studies did not attempt to differentiate infection from contamination, CNST may represent contamination in many cases (174) .

At 77%, the prevalence of antibiotic prescribing was high and incongruent with the relatively low prevalence of bacterial infections. This outcome remained consistent with our previous publication (4) . Of note, clinical guidelines for COVID-19 recommendations varied with respect to the use of empiric antibiotics, particularly in critically ill patients (195) (196) (197) (198) . Differences in the recommended approach to antibiotic prescribing may explain why the use of antibiotics remained higher than prevalence of bacterial infections. Our findings support a more judicious approach, particularly in patients outside of the ICU.

A limitation of this review is that these findings are constrained by the quality of the underlying primary literature, as less than one third of included studies were considered to be at low risk of bias. We also noted a high degree of heterogeneity across studies, of which it is not clear whether this reflects a difference in clinical characteristics, diagnostic approaches, and/or clinical practice across settings. However, our findings are relatively consistent across study risk of bias rating and align with those in recent large high-quality observational cohort studies (83, 161) . A second limitation is our focus on microbiological identification of bacterial infection. 

Concept and design: All authors. Acquisition, analysis, or interpretation of data: All authors.

Critical revision of the manuscript for important intellectual content: All authors.

Administrative, technical, or material support: All authors.

This project was carried out as part of routine work.

The authors would like to thank:

Ashley Farrell, BA, MLIS, AHIP, Information Specialist for her support with formulating and executing the search strategy for this review.

Parmvir Parmar MD, FRCPC for his support in full text screening for this review.

We thank the Toronto Antimicrobial Resistance Research Network (TARRN), an interprofessional forum of clinicians and researchers that acted as a venue for bringing together this research team, and a repository for our rapid review. 

Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and metaanalysis

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

S2666524721000902

Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study

Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis

State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia

Hospital-Acquired Infections in Critically Ill Patients With COVID-19

S0012369221006796

Cochrane Rapid Reviews Interim Guidance from the Cochrane Rapid Reviews Methods Group

Bacterial coinfection and secondary infection in patients with COVID-19: a living rapid review and metaanalysis

Understanding interobserver agreement: the kappa statistic

Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement

Arcsine-based transformations for meta-analysis of proportions: Pros, cons, and alternatives

Meta-analysis of Proportions Using Generalized Linear Mixed Models

Cochrane Handbook for Systematic Reviews of Interventions

Predictors and Microbiology of Co-Infection in Patients with COVID-19: Living Rapid Review Update and Meta-Regression Statistical Code

Factors that may impact on immunosenescence: an appraisal

The Impact of Tracheal Intubation on Host Defenses and Risks for Nosocomial Pneumonia

Clinical Characteristics and Predictors of 28-Day Mortality in 352 Critically Ill Patients with COVID-19: A Retrospective Study

Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer

Annane) FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis), RHU RECORDS (Rapid rEcognition of CORticosteroiD resistant or sensitive Sepsis), Department of Intensive Care

Hospital Admission in Children and Adolescents With COVID-19

Increased mortality in patients with severe SARS-CoV-2 infection admitted within seven days of disease onset

Early predictors of inhospital mortality in patients with COVID-19 in a large American cohort

Tidsskr Den Nor Laegeforening Tidsskr Prakt Med Ny Raekke

A cohort of patients with COVID-19 in a major teaching hospital in Europe

COVID-19 in a designated infectious diseases hospital outside Hubei Province

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Incidence of bacterial and fungal bloodstream infections in COVID-19 patients in intensive care: An alarming "collateral effect

Risk for In-Hospital Complications Associated with COVID-19 and Influenza -Veterans Health Administration, United States

Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study

Primary Respiratory Bacterial Coinfections in Patients with COVID-19

Risk factors for death in 1859 subjects with COVID-19

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet

Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study

Analysis of the risk factors for nosocomial bacterial infection in patients with COVID-19 in a tertiary hospital

Bacterial coinfections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster

Comparison of Clinical Features and Outcomes in Critically Ill Patients Hospitalized with COVID-19 versus Influenza

Cause-specific death in hospitalized individuals infected with SARS-CoV-2: more than just acute respiratory failure or thromboembolic events

Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care

Outcomes of COVID-19 hospitalized patients previously treated with renin-angiotensin system inhibitors

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Differentiating influenza from COVID-19 in patients presenting with suspected sepsis

Clinical Features of COVID-19 Patients in Xiaogan City

COVID-19 with Different Severity: A Multi-center Study of Clinical Features

Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics

Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions

Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, multicentre study

Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study

Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Clinical characteristics, outcomes and prognosticators in adult patients hospitalized with COVID-19

Bloodstream infections in critically ill patients with COVID-19

Bacterial infections and patterns of antibiotic use in patients with COVID-19

Clinical Course and Factors Associated With Hospitalization and Critical Illness Among COVID-19 Patients in Chicago, Illinois

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

The mncp-spi score predicting risk of severe covid-19 among mild-pneumonia patients on admission

Comparative Analysis of 95 Patients with Different Severity in the Early Outbreak of COVID-19 in Wuhan

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis

Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study

Prognostic Factors for Severe Coronavirus Disease 2019 in Daegu

Clinical and laboratory findings from patients with COVID-19 pneumonia in Babol North of Iran: a retrospective cohort study

Risk factors for mortality of 557 adult patients with COVID 19 in Babol, Northern Iran: a retrospective cohort study

Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study

Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study. Open Forum Infect Dis

Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands

Outcomes Among HIV-Positive Patients Hospitalized With COVID-19

Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study

IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections

United States(Kimmig, Wu, Mutlu) Section of Pulmonary and Critical Care Medicine

Assessment of Respiratory Bacterial Coinfections among Severe Acute Respiratory Syndrome Coronavirus 2-Positive Patients Hospitalized in Intensive Care Units Using Conventional Culture and BioFire, FilmArray Pneumonia Panel plus Assay. Open Forum Infect Dis

Predictors and outcomes of healthcare-associated infections in COVID-19 patients

Kethireddy) Department of Pulmonary&Critical Care, Northeast Georgia Health System

Characteristics of COVID-19 Patients with Bacterial Co-infection Admitted to the Hospital from the Emergency Department in a Large Regional Healthcare System

Secondary infection among hospitalized COVID-19 patients: A retrospective cohort study in a tertiary care setting

Community Acquired Co-infection in COVID-19: A Retrospective Observational Experience

Characteristics and early outcomes of patients hospitalised for covid-19 in North Zealand, Denmark

Plasma albumin levels predict risk for nonsurvivors in critically ill patients with COVID-19

Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Immune-related factors associated with pneumonia in 127 children with coronavirus disease 2019 in Wuhan

Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19

Increased susceptibility to intensive care unit-acquired pneumonia in severe COVID-19 patients: a multicentre retrospective cohort study. Ann Intensive Care

Analysis of the first 100 patients with COVID-19 admitted to internal medicine wards at the Hospital de Clinicas

Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong-A Territory-Wide Cohort Study

Ventilatorassociated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study. Ann Intensive Care

Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study

Karakitsos) Critical Care Department, King Saud Medical City, Riyadh, Saudi Arabia(Mady) Department of Anesthesiology and Critical Care

Ventilatorassociated pneumonia in critically ill patients with COVID-19

Bacterial co-infections and antibiotic resistance in patients with COVID-19

COVID-19 related deaths in an urban academic medical center in Brooklyn -A descriptive case series

Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission

Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in

Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study

Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab

The first 100 cases of covid-19 in a hospital in madrid with a 2-month follow-up

Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y Leon

A Prospective Cohort of SARS-CoV-2-Infected Health Care Workers: Clinical Characteristics, Outcomes, and Follow-up Strategy

Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge

Increased secondary infection in COVID-19 patients treated with steroids in New York City

Should We Prescribe Antibiotics in Older Patients Presenting COVID-19 Pneumonia?

High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia

Clinical course of coronavirus disease-2019 in pregnancy

Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study

Late onset infectious complications and safety of tocilizumab in the management of COVID-19

Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study

Clinical course and potential predictive factors for pneumonia of adult patients with coronavirus disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand

Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6

Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial

Predictors of severity and co-infection resistance profile in COVID-19 patients: First report from upper Egypt

Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease

COVID-19 in solid organ transplant recipients: No difference in survival compared to general population

Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors

Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study

Outcomes in patients with severe COVID-19 disease treated with tocilizumab: A case-controlled study

Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis

Rates of bacterial coinfections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship

Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study

Tocilizumab in patients hospitalized with Covid-19 pneumonia

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study

Bacteremia and Blood Culture Utilization During COVID-19 Surge in New York City

Scoring systems for predicting mortality for severe patients with COVID-19

CoV-2-related pneumonia cases in pneumonia picture in Russia in March-May 2020: Secondary bacterial pneumonia and viral co-infections

Clinical characteristics of imported and secondgeneration coronavirus disease 2019 (COVID-19) cases in Shaanxi outside Wuhan, China: A multicentre retrospective study

Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study

Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge

Communityacquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Low incidence of co-infection, but high incidence of ICU-acquired infections in critically ill patients with COVID-19

Antimicrobial prescribing practices at a tertiary-care center in patients diagnosed with COVID-19 across the continuum of care

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial

Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. JAC-Antimicrob Resist

Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data

Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit

Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease

Clinical Characteristics and Risk Factors of Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients in Beijing, China: A Retrospective Study

Epidemiological and clinical characteristics of fifty-six cases of COVID-19 in Liaoning Province

Analysis of the clinical characteristics of 77 COVID-19 deaths

Household transmission of SARS-CoV-2

An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London

Clinical characteristics of 199 discharged patients with COVID-19 in Fujian Province: A multicenter retrospective study between

Compare the epidemiological and clinical features of imported and local COVID-19 cases in Hainan, China

Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)

Household Transmission of SARS-CoV-2

Development and validation of the HNC-LL score for predicting the severity of coronavirus disease 2019

Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China

Guo) Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, Department of Radiology

Risk factors analysis of COVID-19 patients with ARDS and prediction based on machine learning

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

S2213260020300795

Clinical characteristics of a group of deaths with COVID-19 pneumonia in Wuhan, China: A retrospective case series

Clinical characteristics and outcomes of coronavirus disease 2019 infections among diabetics: A retrospective and multicenter study in China

Low prevalence of bloodstream infection and high blood culture contamination rates in patients with COVID-19

Patients with COVID-19 in 19 ICUs in Wuhan, China: A cross-sectional study

Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients With Coronavirus Disease

Clinical Characteristics of Patients With Progressive and Non-progressive Coronavirus Disease 2019: Evidence From 365 Hospitalised Patients in Honghu and Nanchang

Comparison of clinical characteristics of COVID-19 between elderly patients and young patients: a study based on a 28-day follow-up

The modified NUTRIC score can be used for nutritional risk assessment as well as prognosis prediction in critically ill COVID-19 patients

Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses

The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. BMC Infect Dis

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dexamethasone in Hospitalized Patients with Covid-19

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

Microbial cause of ICU-acquired pneumonia: hospitalacquired pneumonia versus ventilator-associated pneumonia

Pathogens Associated With Repeat Versus Single Central-Line-Associated Bloodstream Infections, Acute-Care Hospitals

COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital

COVID-19 Treatment Guidelines Panel. COVID-19 Treatment Guidelines

World Health Organization. Clinical Management of COVID-19 Interim Guidance

World Health Organization

Recommendations for antibacterial therapy in adults with COVID-19 -an evidence based guideline

The role of co-infections and secondary infections in patients with COVID-19

J o u r n a l P r e -p r o o f CNST (217) Chlamydia (5) Enterococcus (65) Enterobacter (42) S. aureus (332)Escherichia (99) S. pneumoniae (40) Haemophilus (38)